Further experience with Quingestanol (cas 10592-65-1) acetate as a postcoital oral contraceptive

Add time:08/17/2019    Source:sciencedirect.com

A previous report based on investigations in Mexico suggested that Quingestanol (cas 10592-65-1) acetate might have potential as a postcoital oral contraceptive at a 800 mcg dose. This concept was based on some 1,000 cycles of therapy with no pregnancies in patients preselected to have 2 to 4 coital acts per week. Additional patients were then enrolled in this and two other centers. In the two new centers, patients were not preselected for frequency of intercourse. They accumulated some 3,400 cycles with a pregnancy rate of over 20 per 100 women years. The patients in the original center continued to take at least 2 to 4 doses the first two weeks regardless of coital frequency. They totaled some 5,500 cycles of experience with a 0.6 rate. The failure of the expanded studies in the general population was related to their coital frequency of only 8 per cycle. When doses of steroid were increased to 1.5 or 2.0 mg, the pregnancy rate declined considerably but the incidence of intermenstrual bleeding became unacceptable. These data indicated that the routine usage of the steroid as a postcoital contraceptive in the general patient population was probably not possible.

We also recommend Trading Suppliers and Manufacturers of Quingestanol (cas 10592-65-1). Pls Click Website Link as below: cas 10592-65-1 suppliers

Prev:Clinical study of a once-a-month oral contraceptive: Quinestrol-Quingestanol (cas 10592-65-1)
Next:Continuous microdose (0.3 mg) Quingestanol (cas 10592-65-1) acetate as an oral contraceptive agent)